(S (NP (DT This) (NN paper)) (VP (VBZ explores) (SBAR (IN whether) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN drug) (NNS reviews)) (CC and) (NP (JJ social) (NNS media))))) (VP (MD could) (VP (VB be) (ADJP (VBN leveraged) (PP (IN as) (NP (NP (JJ potential) (JJ alternative) (NNS sources)) (PP (IN for) (NP (NP (NP (NN pharmacovigilance)) (PP (IN of) (NP (JJ adverse) (NN drug) (NNS reactions)))) (-LRB- -LRB-) (NP (NNS ADRs)) (-RRB- -RRB-))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD examined) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (NNP BERT)))) (PP (IN alongside) (NP (NP (CD two) (NNS variants)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN trained) (PP (IN on) (NP (NP (JJ biomedical) (NNS papers)) (, ,) (NP (NN BioBERT7)) (, ,) (CC and) (NP (NP (JJ clinical) (NNS notes)) (, ,) (NP (JJ Clinical) (NN BERT8)))))))))))) (. .))
(S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (CD 8) (JJ different) (NNP BERT) (NNS models)))) (VP (VBD were) (ADJP (JJ fine) (HYPH -) (VBN tuned)) (NAC (CC and) (PP (VBN compared) (PP (IN across) (NP (NP (CD three) (JJ different) (NNS tasks)) (PP (IN in) (NP (NN order) (S (VP (TO to) (VP (VB evaluate) (NP (PRP$ their) (JJ relative) (NN performance)) (PP (IN to) (NP (CD one) (DT another))) (PP (IN in) (NP (DT the) (NN ADR) (NNS tasks))))))))))))) (. .))
(S (NP (DT The) (NNS tasks)) (VP (VBP include) (NP (NP (NP (NN sentiment) (NN classification)) (PP (IN of) (NP (NN drug) (NNS reviews)))) (, ,) (NP (NP (NN presence)) (PP (IN of) (NP (NP (NN ADR)) (PP (IN in) (NP (NN twitter) (NNS postings)))))) (, ,) (CC and) (NP (NP (VBN named) (NN entity) (NN recognition)) (PP (IN of) (NP (NP (NNS ADRs)) (PP (IN in) (NP (NN twitter) (NNS postings)))))))) (. .))
(S (NP (NNP BERT)) (VP (VBZ demonstrates) (NP (PRP$ its) (NN flexibility)) (PP (IN with) (NP (NP (JJ high) (NN performance)) (PP (IN across) (NP (DT all) (CD three) (ADJP (NP (JJ different) (NN pharmacovigilance)) (VBN related)) (NNS tasks)))))) (. .))
